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Abstract
Background: Cancer survivors may be at increased risk of cardiovascular diseases, but little is known about whether
prescribing guidelines for the primary prevention of cardiovascular disease are adequately implemented in these
patients. We compared levels of statin initiation and cessation among cancer survivors compared to the general
population to determine differences in uptake of pharmaceutical cardiovascular risk prevention measures in these
groups.
Methods: The study population included individuals aged ≥40 during 2005–13 within the UK Clinical Practice
Research Datalink primary care database. Within this population we identified cancer survivors who were alive and
under follow-up at least 1 year after diagnosis, and controls with no cancer history. Follow-up time prior to cancer
diagnosis was included in the control cohort. Using logistic regression, we compared these groups with respect to
uptake of statins within 1 month of a first high recorded cardiovascular risk score. Then, we used Cox modelling to
compare persistence on statin therapy (time to statin cessation) between cancer survivors and controls from the
main study population who had initiated on a statin.
Results: Among 4202 cancer survivors and 113,035 controls with a record indicating a high cardiovascular risk score,
23.0% and 23.5% respectively initiated a statin within 1 month (adjusted odds ratio 0.98 [91.8–1.05], p = 0.626). Cancer
survivors appeared more likely to discontinue statin treatment than controls (adjusted hazard ratio 1.07 [1.01–1.12],
p = 0.02). This greater risk of discontinuing was only evident after the first year of therapy (p-interaction < 0.001).
Interpretation: Although cardiovascular risk is thought to be higher in cancer survivors compared to the general
population, cancer survivors were no more likely to receive statins, and marginally more likely to cease long-term
therapy, than general population controls. There may be an opportunity to mitigate the suspected higher
cardiovascular risk in the growing population of cancer survivors by improving uptake of lipid-lowering treatment
and persistence on therapy.
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Introduction
Advances in cancer detection and treatment over the
past 20 years have led to considerable improvements in
cancer survival [1, 2]. Consequently, the number of
people living with a history of cancer – “cancer survi-
vors” - is steadily increasing [1]. Some cancers are in-
creasingly thought of as chronic diseases that require
evidence based multidisciplinary care for the prevention
and management of comorbidities and sequelae [3–6].
Recent evidence has demonstrated that cancer survivors
are at increased risk of cardiovascular disease (CVD) com-
pared to the general population [7] and that in certain
populations (e.g. breast cancer survivors) CVD competes
with cancer as the leading cause of death [8, 9]. This is
likely to be due to shared risk factors (e.g. obesity and to-
bacco use) and potential cardiotoxic effects of systemic
therapies and radiotherapy [10, 11]. It has been suggested
that sub-optimal primary prevention may also be respon-
sible [12, 13]. In the absence of specific cardiovascular risk
prevention guidelines targeted at cancer survivors, such
individuals would be expected to follow strategies recom-
mended for the general population, i.e. reducing
lifestyle-related risk factors, and pharmacological manage-
ment of lipid and blood pressure [14]. Since 2005, UK
guidelines on primary CVD prevention (Additional file 1:
Table S1) have recommended all people with high cardio-
vascular risk (i.e. 10 year predicted risk ≥20%) be offered
statin therapy [15]. Current risk assessment tools do not
take possible additional risks associated with previous can-
cer into account, and may under-estimate vascular risk
among cancer survivors. Statin uptake rates in the general
population appear to be low, with a number of studies
finding that only around one fifth to one third of patients
at high cardiovascular risk were actually prescribed a
statin [16–19]. To our knowledge, equivalent statin uptake
rates in cancer survivors have not previously been
quantified.
In order to best target initiatives to improve gaps in
survivorship care, we need to confirm whether cardio-
vascular risk prevention strategies are being followed in
this vulnerable population, and whether cancer survivors
persist with long-term medications intended to reduce
their cardiovascular risk. We therefore aimed to com-
pare use of lipid-lowering drugs between cancer survi-
vors and control patients with no previous cancer,
specifically focusing on prescribing of statins to those
scored as high CV risk; and the time to statin discon-
tinuation, among those starting a statin.
Methods
Data source and main study population
We conducted a longitudinal population-based open co-
hort study using Clinical Practice Research Datalink
(CPRD) GOLD data. CPRD GOLD is a primary care
database containing the anonymised medical records for
over 15 million patients from 674 general practices in
the United Kingdom (UK) [20]. CPRD GOLD data,
which are collated daily from participating practices that
use Vision software, include information on demograph-
ics, symptoms, tests, diagnoses, and prescriptions, and
are subject to data quality checks. Diagnoses in CPRD
are typically recorded using National Health Service
(NHS) Read codes. Approximately 7% of the UK popula-
tion are included, with patients broadly representative of
the UK general population in terms of age, sex and eth-
nicity [20]. In the UK, the General Practitioner (GP) is
the first point of contact and “gatekeeper” for most
non-emergency NHS care; the vast majority of the popu-
lation is registered with a GP [21].
The study period was 1st January 2005 to 31st Decem-
ber 2013 because during this period national guidelines
(Additional file 1: Table S1) remained constant in
recommending statin therapy for people with predicted
cardiovascular risk ≥20% over 10 years, for primary pre-
vention. Patients who were 40 years or older during the
study period and had at least 12 months of research
quality CPRD follow-up prior to entering the cohort
were included; follow-up began on the latest of 1/1/
2005, the patient’s 40th birthday, or the date on which
12 months of follow-up had been accumulated in CPRD;
follow-up ended on the earliest of 31/12/2013, the last
data collection date, or the end of follow-up in CPRD.
Patients with a CVD event (Additional file 2: Table S2)
prior to entering the study were excluded (as our focus
was on primary CVD prevention).
Read code lists to identify cancer diagnoses were de-
veloped using the methodology described in a previous
study [22]. All person-time was categorised into “never--
cancer”, “first year post-cancer diagnosis” and “≥ 1 year
post-cancer diagnosis”. Person-time in the ≥1 year
post-cancer diagnosis category made up the cancer sur-
vivor group, while “never-cancer” person-time made up
the control group. Person-time in the first year
post-cancer diagnosis was not analysed further. People
could contribute to more than one of the comparison
groups, if they developed cancer during follow-up, but
could only contribute to one exposure group at any
given moment of follow-up. From this overall study
population, sub-cohorts were defined to address each of
our objectives, as described in the sections below.
Descriptive analysis
Baseline characteristics were described for the overall
study population and sub-populations (defined below).
We also described the proportion of patients with at
least one measurement recorded in the past 5 years for
each of: blood pressure (diastolic and systolic recorded
on the same day), lipids (total cholesterol and/or
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high-density lipoprotein cholesterol (HDL) and/or chol-
esterol/HDL ratio), and 10 year predicted cardiovascular
risk score (Framingham, QRisk, ASSIGN, Joint British
Society (JBS), or unspecified; Read terms used to identify
cardiovascular risk scores are included in Additional file 3:
Table S3). This description of blood pressure/lipids/risk
score recording was stratified by cancer survivor / con-
trol status, gender and specific points of age (namely at
age 45, and in steps of 5 years up to 75); and within
strata, was restricted to individuals under follow-up at
the given age and with at least 5 years of prior follow-up
in CPRD.
Uptake of statins among those recorded as high CVD risk
To assess uptake of statin therapy among patients with
high recorded CVD risk, all patients from the overall
study population with a first ever Read code or quantita-
tive record indicating predicted 10 year cardiovascular
risk of ≥20% in CPRD and no previous statin use were
included in the ‘high cardiovascular risk cohort’. To ex-
clude patients with previous high risk scores, patients
were required to have at least 12 months of research
quality follow-up in CPRD prior to the first high risk
score record. Patients were excluded if their follow-up
ended during the 31 day period after the high cardiovas-
cular risk score, leaving inadequate eligible time to as-
sess prescription of a statin within 1 month. For this
analysis, patients were grouped as cancer survivors or
controls based on their status on the date of their first
high CVD risk record. The outcome was statin uptake,
defined as having a first prescription for statin therapy
(defined using the codes in Additional file 4: Table S4)
within 31 days of the first high cardiovascular risk score.
The association between cancer survivorship and statin
uptake was assessed using logistic regression. First, the
unadjusted association was estimated, then we adjusted
for age at baseline (i.e. at first high cardiovascular risk
score, in 10 year categories) and gender as a-priori con-
founders. The following potential confounders were con-
sidered one at a time: practice Index of Multiple
Deprivation quintile (a proxy for socio-economic status)
[23]; body mass index (BMI, categorised as underweight
(< 18.5 kg/m2), healthy weight (18.5-25 kg/m2) and over-
weight/obese (> 25 kg/m2)); total cholesterol (categorised as
normal (< 5 mmol), moderate-high (5-8 mmol) and high (>
8 mmol)); smoking status (never, current, ex-smoker); alco-
hol consumption (non-drinker, ex-drinker, high/medium/
low/unknown-level current drinker); chronic kidney disease
(CKD), diabetes, and chronic liver disease at baseline (both
defined using Read codes); and calendar time (split into
2005–07, 2008–10, 2011–13 to account for the marked in-
crease in statin prescribing demonstrated in previous CPRD
research over the study time period [24]). These covariates
were only included in the final model if the absolute change
to the odds ratio (OR) was greater than 10% when the sin-
gle variable was added to the unadjusted model. Only par-
ticipants with complete data for the relevant confounder
were included in the stepwise testing analyses (adjusted and
comparative a-priori models).
We investigated whether calendar period modified the
association between cancer and initiation of a statin by
adding calendar period to the model as an interaction
term - the stratified ORs were assessed and a likelihood
ratio test was used to compare the models with and with-
out the interaction term. There was not considered to be
any a priori reason to test for any other interactions.
Time to statin discontinuation among those starting a
statin
To assess statin persistence, patients from the overall
study population who started a statin for primary pre-
vention (i.e. with no previous CVD record) during the
study time period were included in the ‘statin initiator
cohort’. To exclude prevalent statin users, patients were
required to have at least 12 months of research quality
follow-up prior to first prescription. For this analysis, pa-
tients were grouped as cancer survivors or controls
based on their status on the date of their first statin pre-
scription. The outcome was the time from statin initi-
ation to first cessation of therapy, calculated from
prescription records. The end date of each prescription
was calculated by dividing the quantity prescribed by the
daily dose where this information was available. Where
duration could not be calculated, the modal prescription
duration (28 days) was assumed. If there was no repeat
prescription within 90 days after the estimated end date
of a prescription, a patient was defined as having ceased
therapy at the estimated end date. A multivariate Cox
model was built, with time since statin initiation as the
underlying time scale and with age (time-updated), gen-
der, BMI, smoking status and diabetes (time updated) in-
cluded as a priori confounders. All regression analyses
were restricted to individuals with complete data for
these confounders. Other candidate confounders were
assessed and added to the model using the same
model-building strategy as described for the analysis of
statin uptake (above).
We investigated an interaction between cancer sur-
vivorship and calendar period as uptake of statins varies
over time and drivers of this may differ in cancer survi-
vors versus the general population. We also considered
heterogeneity by time since cancer diagnosis. The pro-
portional hazards assumption was assessed by testing for
an interaction between cancer survivor status and time
since statin initiation (categorised as < 0.5, 0.5–1, > 1–2,
> 2 years). In a sensitivity analysis, the Cox model time
scale was switched to age (to control more closely for
age), and time since initiation was adjusted for as a
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time-varying covariate. Robust standard errors were
used in all analyses to account for clustering at GP
practice level.
Results
Overall, 3,369,849 individuals aged 40 years or over dur-
ing the study period 2005 to 2013 were included in the
main study cohort (Fig. 1). Of the main study cohort
131,676 contributed person-time to the cancer survivors
(exposed) and 3,324,152 to the general population con-
trols (unexposed). Demographics and baseline character-
istics of the study populations are described in Table 1.
Cancer survivors were older on average than controls
(median: 67 years vs. 51 years), and a higher proportion
Fig. 1 Flow chart of included study participants
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Table 1 Baseline characteristics for the main study cohort and sub-populations by cancer survivor (> = 1 year) status
Main Study Cohorta High Cardiovascular Risk Cohortb Statin Initiator Cohortc
Cancer Survivor Control Cancer Survivor Control Cancer Survivor Control
n = 131,676 n = 3,324,152 n = 4202 n = 113,035 n = 12,142 n = 366,280
n (%) n (%) n (%) n (%) n (%) n (%)
Sex
Male 58,587 (44.7) 1,618,820 (48.70) 2659 (63.3) 80,264 (71.0) 5959 (49.1) 194,430 (53.1)
Female 72,823 (55.3) 1,705,299 (51.30) 1543 (36.7) 32,771 (29.0) 6183 (50.9) 171,848 (46.9)
Age (years)
Median (IQR) 66.5 (57.5–75.5) 50.5 (42.1–62.3) 69.1 (64.2–72.9) 64.2 (58.4–69.8) 68.9 (62.4–75.1) 62.6 (54.9–70.2)
40–49 14,117 (10.7) 1,529,272 (46.0) 27 (0.6) 5410 (4.8) 351 (2.9) 45,132 (12.3)
50–59 24,564 (18.6) 775,972 (23.3) 368 (8.8) 27,121 (24.0) 1630 (13.4) 96,664 (26.7)
60–69 38,078 (28.9) 521,777 (15.7) 1815 (43.2) 50,847 (45.0) 4393 (36.2) 125,540 (34.3)
70–79 33,983 (25.8) 303,231 (9.1) 1765 (42.0) 26,713 (23.6) 4086 (33.7) 73,598 (20.1)
80+ 20,934 (15.9) 193,900 (5.8) 227 (5.4) 2944 (2.6) 1682 (13.7) 25,346 (6.9)
BMI (kg/m2)
Mean (SD) 26.9 (5.3) 26.9 (5.3) 28.3 (4.8) 27.8 (5.1) 28.2 (5.4) 28.7 (5.6)
< 18.5 2748 (2.1) 48,109 (1.4) 50 (1.2) 897 (0.8) 131 (1.1) 2906 (0.8)
18.5–25 46,037 (35.0) 1,130,838 (34.0) 1127 (26.8) 27,294 (24.2) 3175 (26.9) 86,962 (24.5)
≥ 25 74,375 (56.5) 1,736,648 (52.2) 2925 (69.6) 81,734 (72.3) 8504 (72.0) 265,128 (74.7)
Missing 8516 (6.5) 408,557 (12.3) 100 (2.4) 3113 (2.8) 332 (2.7) 11,285 (3.1)
Cholesterol (mmol/L)
Mean (SD) 5.3 (1.2) 5.4 (1.1) 5.7 (1.0) 5.8 (1.1) 6.0 (1.3) 6.1 (1.3)
Normal (< 5) 42,503 (32.3) 796,230 (23.9) 898 (21.4) 21,543 (19.1) 2242 (18.7) 58,780 (16.2)
Mod (5–8) 62,529 (47.5) 1,405,997 (42.3) 3137 (74.6) 85,221 (75.4) 8965 (74.8) 278,848 (76.9)
High (> 8) 1704 (1.5) 38,297 (1.2) 92 (2.2) 3316 (2.9) 775 (6.47) 25,032 (6.9)
Missing 24,940 (18.9) 1,083,578 (32.6) 75 (1.8) 2955 (2.6) 157 (1.29) 3640 (1.0)
Smoking status
Never 46,606 (35.4) 1,358,706 (40.9) 1194 (28.4) 29,306 (25.9) 3729 (30.7) 118,728 (32.4)
Ex 61,969 (47.1) 965,510 (29.1) 2133 (50.8) 46,494 (41.2) 6572 (54.1) 166,482 (45.5)
Current 22,627 (17.2) 885,915 (26.6) 875 (20.8) 37,190 (32.9) 1840 (15.2) 80,841 (22.1)
Missing 474 (0.4) 114,021 (3.4) < 5 45 (0.0) < 5 299 (0.1)
Alcohol status (non- ex- current drinker)
Non 25,030 (19.0) 577,211 (17.4) 742 (17.7) 18,139 (16.1) 2500 (27.3) 75,516 (27.5)
Ex 3778 (2.84) 74,249 (2.2) 162 (3.9) 4079 (3.6) 447 (4.9) 13,002 (4.7)
Current
light 48,354 (36.7) 1,042,681 (31.3) 1629 (38.8) 40,996 (36.3) 4868 (53.1) 140,039 (51.0)
moderate 4776 (3.6) 106,934 (3.2) 224 (5.3) 5904 (5.2) 503 (5.5) 15,837 (5.8)
heavy 5025 (3.8) 150,372 (4.5) 254 (6.0) 9229 (8.2) 562 (6.1) 19,668 (7.2)
unknown 2819 (2.1) 74,769 (2.3) 117 (2.8) 4193 (3.7) 280 (3.1) 10,747 (3.9)
Missing 41,894 (31.8) 1,297,936 (39.0) 1074 (25.6) 30,495 (27.0) 2982 (24.6) 91,474 (25.0)
Medical history
Diabetes 12,045 (9.2) 153,405 (4.6) 187 (4.5) 5308 (4.7) 2239 (18.4) 69,156 (18.9)
CKD 9577 (7.3) 28,419 (0.9) 368 (8.8) 5465 (4.8) 1450 (12.0) 24,464 (6.7)
Chronic liver disease 2223 (1.7) 39,429 (1.2) 75 (1.8) 7975 (1.8) 221 (1.8) 6378 (1.7)
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were females (55.3% vs. 51.3%). As patients enter the can-
cer survivor group later than the general population con-
trol group, the proportion of patients followed up from
later calendar years was greater in the cancer survivor
group (26.1% vs. 12.9% for 2011–2013). The baseline
prevalence of diabetes and CKD were substantially higher
among cancer survivors compared with controls (9.2% vs
4.6% respectively for diabetes, and 7.3% vs 0.9% for CKD).
Figure 2 describes the proportion of individuals from the
full study population with a BP, cholesterol measurement,
or a cardiovascular risk score recorded at least once in the
past 5 years, by age, gender and exposure status; a table of
the same results presented numerically is provided in
Additional file 5: Table S5. Overall, the highest level of
monitoring was observed for BP (range: 60.0% to 97.2%),
followed by cholesterol (range: 32.6% to 80.1%). BP and
cholesterol monitoring were consistently higher in cancer
survivors than controls, across all ages and gender with
the exception of cholesterol monitoring in women which
appeared to be similar between cancer survivors and con-
trols. There was suboptimal recording of cardiovascular
risk scores for both sexes and in all age groups, regardless
of cancer status (range: 5.6% to 21.3%). Cancer survivors
tended to have either similar or marginally better record-
ing of cardiovascular risk compared to controls of the
same age and gender. We repeated these analyses
post-hoc restricting to patients without CKD or diabetes,
in case baseline differences in these diseases affected the
comparison between cancer survivors and controls. Simi-
lar patterns were seen.
Uptake of statins among those recorded as high CVD risk
The ‘high cardiovascular risk cohort’ included 118,012
individuals (Fig. 1). Of these, 4202 individuals were can-
cer survivors at the time of their first high risk score and
113,035 were controls; cancer survivors were more likely
than controls to be older (median age 69.1 vs 64.2 years),
female (36.7% vs. 29.0%), current non-smokers (79.2%
vs. 67.1%), less deprived (29.2% vs 24.0% in the lower
two deprivation quintiles) and to have CKD (8.8% vs.
4.8%; Table 1, middle columns). There were also small
but statistically significant differences in cholesterol and
alcohol status between the groups.
Nine hundred sixty-eight of 4202 cancer survivors
(23.0%) and 26,606 of 113,035 controls (23.5%) initiated
a statin within a month of their first high cardiovascular
risk score. There was no evidence of association between
cancer survivorship and statin initiation in the initial un-
adjusted analysis: OR 0.97 (95% CI: 0.90–1.05, p = 0.443,
Table 2). There was evidence that statin initiation was
more likely among females, those with BMI ≥25 kg/m2,
total cholesterol > 5 mmol/L, ex-smokers, and those
with diabetes or CKD, and less common in people aged
over 80 years, heavy drinkers, underweight individuals,
and those in later calendar periods. None of the tested
covariates individually changed the association between
cancer survivorship and statin initiation by more than
10%; the maximum change being 1.5%. Therefore only
age and gender were included in the final logistic regres-
sion model as a priori confounders associated with both
cancer status and statin initiation. The final adjusted
Table 1 Baseline characteristics for the main study cohort and sub-populations by cancer survivor (> = 1 year) status (Continued)
Main Study Cohorta High Cardiovascular Risk Cohortb Statin Initiator Cohortc
Cancer Survivor Control Cancer Survivor Control Cancer Survivor Control
n = 131,676 n = 3,324,152 n = 4202 n = 113,035 n = 12,142 n = 366,280
n (%) n (%) n (%) n (%) n (%) n (%)
Index of Multiple Deprivation quintile
1 (least) 16,993 (12.9) 298,566 (9.0) 641 (15.2) 12,842 (11.4) 1697 (11.1) 40,458 (11.1)
2 12,043 (12.9) 340,205 (10.2) 588 (14.0) 13,616 (12.6) 1607 (13.2) 43,074 (11.8)
3 18,708 (14.2) 384,484 (11.6) 545 (13.0) 14,211 (12.6) 1655 (13.6) 48,491 (13.2)
4 64,007 (48.6) 1,978,653 (59.5) 1894 (45.1) 57,464 (50.8) 5615 (46.2) 188,142 (51.4)
5 (most) 14,985 (11.4) 322,244 (9.7) 434,534 (12.7) 14,902 (13.2) 1586 (13.1) 46,115 (12.6)
Calendar year
2005–07 62,916 (47.8) 2,423,116 (72.9) 623 (14.8) 23,020 (20.4) 4105 (33.8) 156,589 (42.8)
2008–10 34,416 (26.1) 471,289 (14.2) 1681 (40.0) 48,349 (42.8) 4310 (35.5) 124,339 (33.9)
2011–13 34,344 (26.1) 429,747 (12.9) 1898 (45.2) 41,666 (36.9) 3727 (30.7) 85,352 (23.3)
aCovariates were measured at baseline (or closest recording) defined in the ‘main study cohort’ as the date of the start of unexposed (non-cancer) and exposed (≥
1 year post cancer diagnosis) follow-up time. Patients in the Main Study Cohort could contribute person-time to exposed and unexposed cohorts
bBaseline was defined in the ‘high cardiovascular risk cohort’ as the date of the first high cardiovascular risk score. Patients could only be included in one of the
comparison cohorts
cBaseline was defined in the ‘statin initiator cohort’ as the date of the first statin prescription. Patients could only be included one of the comparison cohorts. If a
non-cancer patient developed cancer while on statin therapy they were censored
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odds ratio was 0.98 (95% CI: 0.92–1.05, P = 0.626)
(Table 2). There was no evidence that the association
between cancer survivorship and statin initiation dif-
fered by calendar period (p-interaction = 0.709).
Persistence on statin therapy for primary prevention of
CVD
Three hundred eighty thousand eight hundred fifty-five
individuals were newly prescribed a statin for primary
prevention (Fig. 1). Twelve thousand one hundred
forty-two were cancer survivors at the time of statin ini-
tiation, 366,280 were controls and 2433 were excluded
from the analysis as statins were initiated within 1 year
of cancer diagnosis. Characteristics of the two groups
are described in Table 1 (right hand columns); differ-
ences between the groups were similar to those observed
in the high cardiovascular risk cohort. In the statin sur-
vivor and control group, 6141 (50.6%) and 190,044
(51.9%) individuals discontinued statin therapy over a
median follow-up time of 1.56 and 1.65 years respect-
ively. Following exclusion of subjects with missing
a-priori confounder values, 366,771 subjects (96.9%)
were included in the Cox regression models. The overall
discontinuation rates were 20.7 and 19.8 per 100 person
years for the cancer survivor and general population
groups. The unadjusted hazard ratio (HR) for association
between cancer survivorship and statin discontinuation
was 1.02 (95%CI: 0.96–1.09, p = 0.50; Table 3). Associa-
tions between covariates and statin discontinuation are
also shown in Table 3.
Only the a priori confounders (age, sex, BMI, smoking,
diabetes status) were included in the final model as none
of the other covariates changed the HR for cancer sur-
vivorship by more than 10%. The maximum change was
3.6% with the inclusion of calendar year (HR = 1.02,
0.98–1.06). The final adjusted Cox regression model
Fig. 2 Proportion (%) of individuals with a cardiovascular risk measures recorded in the past 5 years. • Blood pressure recorded = a diastolic and
systolic BP recorded on the same day at least once in the past 5 years. • Cholesterol recorded = total cholesterol and/or high-density lipoprotein
cholesterol and/or cholesterol/HDL ratio recorded at least once in the past 5 years. • Cardiovascular risk score (CVR) recorded = 10 year predicted
cardiovascular risk (Framingham, QRisk, ASSIGN, Joint British Society (JBS), or unspecified) recorded at least once in the past 5 years. • Study
population = 3,369,849 patient main study cohort
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Table 2 Associations between cancer survivorship and covariates, and statin initiation among the high cardiovascular risk cohort
Total n Initiates statin n (%) Crude OR (95% CI) p-value Adjusteda OR (95% CI) p-value
Cancer status (binary)
Non-cancer 113,035 26,606 (23.54) 1 0.443 1
Cancer survivor 4202 968 (23.04) 0.97 (0.90–1.05) 0.98 (0.92–1.05) 0.626
Sex
Males 82,923 18,902 (22.79) 1 < 0.001 1 < 0.001
Females 34,314 8672 (25.27) 1.15 (1.11–1.18) 1.19 (1.15–1.23)
Age (years)
40–49 5437 1301 (23.93) 1 < 0.001 1 < 0.001
50–59 27,489 6402 (23.29) 0.97 (0.90–1.04) 0.96 (0.89–1.03)
60–69 52,662 12,760 (24.23) 1.02 (0.92–1.12) 1.00 (0.90–1.10)
70–79 28,478 6624 (23.26) 0.96 (0.87–1.06) 0.92 (0.83–1.01)
80+ 3171 487 (15.36) 0.58 (0.47–0.71) 0.53 (0.43–0.65)
BMI (kg/m2)
< 18.5 948 136 (14.35) 0.62 (0.53–0.73) < 0.001
18.5–25 28,421 6050 (21.29) 1
≥ 25 84,659 20,779 (24.54) 1.2 (1.17–1.24)
Missing n (%) 3213 (2.74)
Cholesterol (mmol/L)
Normal (< 5) 22,469 2910 (12.95) 1 < 0.001
Moderate - High (5–8) 88,274 22,838 (25.87) 2.36 (2.25–2.49)
High (> 8) 3435 1750 (50.95) 7.1 (6.48–7.78)
Missing n (%) 3059 (2.61)
Smoking status
Never smoker 30,500 6863 (22.5) 1 < 0.001
Ex-smoker 48,627 11,971 (24.62) 1.12 (1.08–1.17)
Current smoker 38,065 8738 (22.96) 1.03 (0.97–1.09)
Missing n (%) 45 (0.04)
Alcohol status
Non-drinker 18,881 4598 (24.35) 1 < 0.001
Ex-drinker 4241 1064 (25.09) 1.04 (0.94–1.15)
Current drinker
light 42,625 10,455 (24.53) 1.01 (0.96–1.06)
moderate 6128 1475 (24.07) 0.98 (0.91–1.06)
heavy 9483 2039 (21.50) 0.85 (0.77–0.94)
amount unknown 4310 1009 (23.41) 0.95 (0.85–1.06)
Missing n (%) 31,569 (26.93)
Medical history
Diabetes 5495 1853 (33.72) 1.7 (1.57–1.85) < 0.001
Chronic kidney disease 5833 1568 (26.88) 1.21 (1.11–1.31) < 0.001
Chronic liver disease 2050 453 (22.10) 0.92 (0.83–1.02) 0.120
Index of Multiple Deprivation quintile
1 (least deprived) 13,483 3133 (23.24) 1 < 0.001
2 14,204 3143 (22.13) 0.94 (0.75–1.17)
3 14,756 3510 (23.79) 1.03 (0.82–1.29)
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provided evidence that the risk of statin discontinuation
was higher in cancer survivors than controls (HR 1.07
95% CI: 1.01–1.12; p = 0.02). The same model built with
age as the underlying timescale and adjusted for time
since statin initiation gave similar results (HR = 1.07,
1.01–1.13, p = 0.02). There was no evidence of inter-
action between cancer survivorship and calendar period
(p-interaction = 0.44) or of differences in the association
according to time since cancer diagnosis (p = 0.70).
However, the association between cancer survivorship
status and statin discontinuation appeared to change
with time since statin initiation (i.e. evidence of
non-proportional hazards, p < 0.001): there was no evi-
dence of an effect of cancer survivorship on statin dis-
continuation in the first 6 months (HR = 1.00 (0.96–
1.04)) or at 6 months to 1 year of therapy (HR = 1.01
(0.94–1.08)); from the second year of therapy onwards,
there was good evidence that the risk of statin discon-
tinuation rate was higher among cancer survivors (HR =
1.09 95% CI = 1.02–1.17; p = 0.008 for the 2nd year of
therapy, and HR = 1.22 95% CI =1.16–1.28; p < 0.001 for
> 2 years after initiation, Fig. 3).
Discussion
There was a low uptake of statins among cancer sur-
vivors with a high recorded cardiovascular risk, with
only 23% starting a statin within 31 days of their high
risk score record; however, there was no evidence of
any difference in uptake between cancer survivors
and non-cancer controls, after adjusting for age and
sex, either overall or within specific calendar periods.
Cancer survivors did appear to be more likely to
discontinue statins than controls, in particular after
the first year since statin initiation, with the risk of
discontinuation 9% (95% CI 2–17%) higher during the
second year since statin initiation (p = 0.013) and 22%
(95% CI 16–28%) higher after 2 years or more on
therapy (p < 0.001).
This is the first large observational database study to
report on initiation of statin therapy in cancer survivors.
Neither are there any directly comparable studies on
statin cessation rates in cancer survivors versus
non-cancer or general population controls. However, our
finding of a greater tendency for cancer survivors to stop
statin therapy is in line with a self controlled retrospect-
ive cohort study in 36,149 breast cancer patients that
used a large health care claims database to compare ad-
herence to oral medications in the 1 year prior to diag-
nosis with 0.5–1.5 years after diagnosis [25]. The study
found adherence to hyperlipidemia medications (based
on medication possession ratio) declined from 83.2 to
57.1% (P < 0.001). Adherence to long term medications
including statins tends to wane with time [26, 27], which
might explain the findings from Yang et al.’s after vs be-
fore comparison. Statin cessation rates for controls in
this study were higher than an earlier study in CPRD
(20.1 vs. 13 per 100 person years, respectively), possibly
explained by the earlier study excluding people with < 2
statin prescriptions and those with < 1 year of follow-up
after their first statin script [28]. One other retrospective
cohort study compared statin discontinuation by indica-
tion (primary versus secondary prevention) in 539 poor
prognosis cancer patients [29]. Over 60% of patients
continued filling statin scripts during the 2 years after
diagnosis and use was similar regardless of indication.
The study can only be generalised to poor prognosis pa-
tients and those who start statin therapy before a cancer
diagnosis, was underpowered to compare number of re-
fills after diagnosis, and lacked a control group.
Our cohort study was large in size, with sufficient power
to produce precise estimates and detect small associations.
CPRD is broadly representative of the UK population in
terms of age, sex and ethnicity [20]. Cancer diagnoses in
CPRD have been previously validated by comparing with
national cancer registration and hospitalization and death
certificate data: > 90% of cancers in CPRD were confirmed
in other data sources, and > 90% of nationally registered
cancers were captured in CPRD [30, 31]. Statin prescrib-
ing is likely to be extremely well captured in CPRD be-
cause the vast majority of statin prescribing takes place in
primary care, and GP prescription data are captured auto-
matically at the point of issue.
Table 2 Associations between cancer survivorship and covariates, and statin initiation among the high cardiovascular risk cohort
(Continued)
Total n Initiates statin n (%) Crude OR (95% CI) p-value Adjusteda OR (95% CI) p-value
4 59,358 13,626 (22.96) 0.98 (0.84–1.16)
5 (most deprived) 15,436 4162 (26.96) 1.22 (0.95–1.56)
Calendar year
2005–07 23,643 6257 (26.46) 1 < 0.001
2008–10 50,030 11,461 (22.91) 0.83 (0.80–0.86)
2011–13 43,564 9856 (22.62) 0.81 (0.78–0.84)
aAdjusted for a priori confounders (age and gender). No other covariates changed the association between cancer survivorship and statin initiation by more than 10%
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Our study also has some limitations. There were
some missing data in BMI and smoking, leading to
omission of patients from the statin cessation regres-
sion analysis (in which only complete cases were in-
cluded); this could lead to selection bias if the
association between the exposure, outcome and covar-
iates was different in patients with and without miss-
ing data. However, the amount of missing data for
BMI and smoking was low (≤ 3.1%) and this is un-
likely to have significantly impacted our results.
Despite the excellent prescribing data in CPRD, statin
initiation might have been underestimated because over
the counter therapy (OTC) is not captured in CPRD.
However based on OTC sales and consumer interviews,
this is not expected to be large issue [32]. Equally, in the
statin initiation analysis, it was impossible to decipher
from the data available whether a statin was offered and
refused by the patient versus not offered. Misclassifica-
tion of statin cessation may also have occurred for indi-
viduals who did not fill the statin prescription and
individuals who received the drug but not take it. This
may lead to an underestimation of statin cessation in
cancer survivors and controls. To our knowledge, there
is no evidence that this would differ between groups, so
this non-differential misclassification may have led to an
underestimation of the difference in cessation between
the groups. While the analyses of statin initiation and
cessation attempted to control for confounding, some
potential confounding factors were not consistently
available for individual patients, including ethnicity, and
family history of CVD, so there is some potential for re-
sidual confounding. Ethnic minorities tend to have lower
cancer rates [33] and are more likely to discontinue sta-
tins [34] which could also produce negative confound-
ing, not controlled for in this study.
During cancer treatment and survivorship, patients are
likely to visit their GP more regularly and measurement
of individual cardiovascular risk factors is increased.
This represents an opportunity to re-inforce the import-
ance of preventative measures in a patient group that is
thought to be at increased risk of CVD. Our findings
suggest that this opportunity has been missed over the
study period (2005–2013). Initiatives such as cancer
treatment summaries and survivorship care plans aim to
increase GP and patient awareness of potential adverse
events associated with cancer treatment [35, 36]. Better
implementation of these initiatives may improve uptake
of measures designed to prevent CVD.
Our study highlights opportunities for further re-
search. We considered cancer survivors in a single
group, but future research might look at whether our re-
sults are dependent upon type of cancer history. Our de-
scriptive analyses demonstrated suboptimal levels of
cardiovascular risk score recording in both cancer survi-
vors and never cancer controls. Future studies are war-
ranted estimating the number of cancer survivors who
are not prescribed statins although they are at high risk
of CVD, whether or not they have a risk score recorded.
Qualitative studies might be carried out to further inves-
tigate the reasons for similarly low levels of statin initi-
ation and slightly higher statin cessation rates among
cancer survivors after 1 year compared to the general
population. Other aspects of cardiovascular risk preven-
tion should also be assessed, including initiation of anti-
hypertensive therapies in at risk patients.
Conclusions
We observed low uptake of statins in both cancer survi-
vors and controls with no history of cancer, with no evi-
dence of difference between the two groups. Cessation of
Fig. 3 Association between cancer survivorshipi and statin discontinuation, by time since statin initiation (index date timescale) ii. Legend: [i]
cancer survivors (> 1 year after a cancer diagnosis) compared to never cancer controls. [ii] From a Cox proportional hazards model with time
since statin initiation as the timescale, adjusted for ‘current’ age, gender, BMI, smoking and diabetes mellitus (time updated)
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statin use is substantial and may be somewhat higher after
1 year of treatment in cancer survivors than in the general
population. Further research might explore the reasons
for this and investigate a wider range of preventative mea-
sures. There may be an opportunity to mitigate the sus-
pected higher cardiovascular risk in the growing
population of cancer survivors by improving uptake of
lipid-lowering treatment and persistence on therapy.
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